SAN JOSE, Calif., USA — April 1, 2026
In a significant advancement in cancer immunotherapy and clinical-stage biotechnology innovation, Anixa Biosciences, Inc. announced positive Phase 1 clinical trial results for its investigational breast cancer vaccine, alongside a strategic agreement with Cytovance Biologics to manufacture cGMP clinical materials for the upcoming Phase 2 trial. The study successfully met all primary endpoints, demonstrating strong safety, tolerability, and immune response generation in 74% of participants, positioning the program for accelerated clinical development and potential future regulatory progress.
Positive Phase 1 Results Validate Safety and Immune Response
The completed Phase 1 trial marks a critical milestone, confirming that the investigational vaccine is safe and well tolerated at the maximum tolerated dose, while also generating robust immune responses in a majority of patients. These findings provide strong early clinical validation of the vaccine’s mechanism of action, which targets α-lactalbumin, a protein typically expressed during lactation but found in various forms of breast cancer.
By stimulating an immune response against α-lactalbumin-expressing tumor cells, the vaccine aims to deliver both therapeutic and preventive benefits, offering a novel approach in oncology where traditional treatments often focus solely on disease management. The ability to generate targeted immune activity highlights the growing importance of precision immunotherapy and antigen-specific cancer vaccines in modern drug development.
cGMP Manufacturing Partnership Supports Clinical Advancement
Advertisement
Unlike traditional GLP-1 therapies, Foundayo is a small-molecule, non-peptide oral drug that can be taken at any time of day, eliminating the need for strict dosing conditions. This innovation is expected to increase patient adherence and expand treatment adoption, particularly among individuals reluctant to use injectable therapies.
Lilly has also introduced a flexible pricing and access model, with eligible patients able to access the therapy for as low as $25 per month with commercial insurance, while self-pay options start at $149 per month, improving affordability and supporting wider market penetration. The drug will be distributed through LillyDirect® with home delivery, followed by availability in retail pharmacies and telehealth platforms, enhancing patient-centric care delivery.
Safety Profile and Regulatory Significance
To support the transition into Phase 2, Anixa has partnered with Cytovance Biologics, a leading contract development and manufacturing organization (CDMO), to produce clinical-grade materials under cGMP standards. This agreement represents a crucial operational step, ensuring that the vaccine meets stringent quality, safety, and regulatory requirements necessary for advanced-stage clinical trials.
The collaboration highlights the importance of scalable manufacturing and regulatory compliance (GMP) in the successful development of biologics and immunotherapies. Cytovance’s expertise in mammalian and microbial expression systems will enable efficient production of the vaccine, supporting timely progression into Phase 2 studies and reinforcing confidence in the program’s clinical and commercial viability.
Innovative Cancer Vaccine Targets Unmet Medical Needs
Anixa’s breast cancer vaccine is being developed in collaboration with Cleveland Clinic, leveraging cutting-edge research in tumor-associated antigens and immune system activation. The vaccine’s focus on “retired proteins” such as α-lactalbumin represents a novel therapeutic strategy, potentially enabling both treatment and prevention of breast cancer, particularly in high-risk populations.
With breast cancer remaining one of the most prevalent cancers globally, the development of effective immunopreventive therapies could transform patient outcomes and reduce long-term disease burden. The planned Phase 2 trial is expected to further evaluate efficacy, dosing, and broader clinical applicability, bringing the program closer to potential regulatory pathways and commercialization opportunities.
Industry Impact and Future Outlook
This development underscores the rapid evolution of biopharmaceutical innovation in oncology, where immune-based therapies and personalized medicine are becoming central to next-generation treatment strategies. The combination of positive early clinical data and established cGMP manufacturing capabilities significantly enhances the likelihood of successful clinical progression.
As the program advances, Anixa’s vaccine could emerge as a first-in-class preventive and therapeutic solution, addressing critical gaps in breast cancer care while aligning with global trends toward early intervention, targeted therapies, and regulatory-driven drug development frameworks.
Source: Anixa Biosciences press release
